Invesco Electric Vehicle Metals Commodity Strategy No K-1 ETF (EVMT) Dividend History

Company News

• Evome Medical Technologies Announces Securities Issuances

  NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) announces it has received conditional approval from the TSX Venture Exchange (the “TSXV”) to complete a shares for services transaction with Beacon Securities Limited (“Beacon”) pursuant to ‎which the Company will issue Beacon ‎504,286 ‎common ‎shares of the Company at a deemed price of ‎$0.1983 per share in satisfaction of $100,000 of advisory services. The shares issuable will be subject to a Canadian ‎four-month hold period.‎

  GlobeNewswire Inc.
• Evome Medical Technologies Announces Update Call with CEO Mike Seckler for Tuesday, June 4, 2024; Provides Update on Strong Q2

  NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today provided details on preliminary estimated revenues and margins from April and May 2024, the first two months of the second quarter. Mike Seckler, Chief Executive Officer of the Company, will also hold a call to update shareholders on the first quarter financials, second quarter progress and future plans of the Company.

  GlobeNewswire Inc.
• Evome Medical Technologies Announces Biodex Generated 100% Sales Growth Comparing April 2024 to January 2024, Plans to Shed Remaining Non-Core Units to Pay Off Remaining Acquisition Debt

  Posting Q1 Financials, Provides Updates on Strong Q2 Posting Q1 Financials, Provides Updates on Strong Q2

  GlobeNewswire Inc.
• Evome Strengthens Major Creditor Relationship After the Sale of the Simbex Unit to Riddell, LOI Related to Simbex Acquisition Debt is Cancelled

  NEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc (the “Company” or “Evome”) highlighted the strengthening credit relationship with Pathward, N.A. (“Pathward”), the Company’s senior lender. As the Company works to sell non-core business units to reduce acquisition debt in an effort to improve operational profitability, Pathward provides working capital to fuel revenue growth of the Company’s new Biodex products. Pathward has featured the strong and growing relationship with Evome as an example of its willingness to fund growth companies:

  GlobeNewswire Inc.
• Evome Sells Simbex R&D Business Unit to Riddell for $4.83M in Cash; Improves Balance Sheet, Reduces Biodex Acquisition Debt

  NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) has reached an agreement with EB Sports Corp. (the “Buyer”)‎, the parent company of Riddell Sports Group, an industry leader in football helmet technology and innovation, to sell Simbex LLC (“Simbex”), the Company’s R&D business unit, for approximately $4.83M in cash. The proceeds will be used to pay down Simbex debt and reduce Evome’s acquisition debt to the seller of its operating subsidiary Biodex Rehab Systems, LLC (“Biodex”), strengthening the Company’s balance sheet, as well as increasing focus on revenue and profit growth from the Biodex product line.

  GlobeNewswire Inc.